Trial Profile

A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spartalizumab (Primary) ; WNT 974 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer; Uveal melanoma
Focus Adverse reactions
Sponsors Novare Pharmaceuticals; Novartis; Novartis Pharmaceuticals

Most Recent Events

06 Sep 2024 Status changed from active, no longer recruiting to completed.
14 Mar 2024 Planned End Date changed from 28 Jun 2024 to 18 Jun 2024.
27 Apr 2023 Planned End Date changed from 23 Nov 2023 to 28 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com